PlexusDx vs AltRx: Which GLP-1 Provider Offers Better Value in 2026?

Last reviewed: September 4, 2026 Last updated: September 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

AltRx advertises promotional rates substantially below PlexusDx through September 5, 2026: month-to-month promotional semaglutide at $89 versus PlexusDx's $189, and month-to-month promotional tirzepatide at $149 versus PlexusDx's $289. AltRx's promotional 12-month prepaid tiers drop further to $75/month calculated rate for semaglutide ($900 upfront) and $125/month calculated rate for tirzepatide ($1,500 upfront), compared to PlexusDx's 6-month commitment rates of $149 semaglutide and $249 tirzepatide.

Three material caveats qualify the AltRx advantage: first, all captured AltRx pricing is promotional and expires September 5, 2026, with standard ongoing rates undocumented as of our September 4, 2026 capture. Second, individual Trustpilot and Reddit reports allege unexpected annual prebilling despite selecting month-to-month plans, though AltRx's website states "cancel anytime." Third, prepaid tiers require full upfront payment. PlexusDx publishes one flat rate with no promotional cycles, no prepayment requirements, and no reported billing conflicts.

At-a-glance comparison

AltRx pricing captured September 4, 2026; PlexusDx pricing captured September 4, 2026. AltRx promotional pricing expires September 5, 2026.

Normalized 12-month cost comparison

Promotional pricing creates a moving target. AltRx's advertised rates expire September 5, 2026, and standard rates are not documented. PlexusDx publishes one rate with no promotional cycles. The following calculations isolate the price variable over 12 months, assuming promotional rates hold (a significant assumption given the September 5 deadline).

Semaglutide injection: month-to-month plans

AltRx promotional month-to-month: $89/month × 12 = $1,068 over 12 months (promotional rate ending September 5, 2026; standard rate unknown). Captured September 4, 2026 from altrx.com/glp1/offer-v9-fl.

PlexusDx month-to-month: $189/month × 12 = $2,268 over 12 months. Captured September 4, 2026 from plexusdx.com/products/semaglutide-injection.

Difference: PlexusDx costs $1,200 more over 12 months at current promotional rates, but this comparison assumes AltRx's promotional rate continues beyond September 5, 2026, which is not supported by the evidence.

Semaglutide injection: multi-month plans

AltRx 12-month prepaid promotional: $900 upfront ($75/month calculated rate) = $900 total over 12 months (promotional rate ending September 5, 2026; standard rate unknown; requires full $900 upfront payment). Captured September 4, 2026.

PlexusDx 6-month commitment: $149/month × 12 = $1,788 over 12 months (our calculation; monthly billing, no upfront payment required).

Difference: AltRx's prepaid promotional tier costs $888 less over 12 months, but requires $900 upfront and expires September 5, 2026, with no documented standard rate thereafter.

Tirzepatide injection: month-to-month plans

AltRx promotional month-to-month: $149/month × 12 = $1,788 over 12 months (promotional rate ending September 5, 2026; standard rate unknown). Captured September 4, 2026.

PlexusDx month-to-month: $289/month × 12 = $3,468 over 12 months. Captured September 4, 2026.

Difference: PlexusDx costs $1,680 more over 12 months at current promotional rates, again assuming AltRx's promotional rate continues beyond September 5.

Tirzepatide injection: multi-month plans

AltRx 12-month prepaid promotional: $1,500 upfront ($125/month calculated rate) = $1,500 total over 12 months (promotional rate ending September 5, 2026; standard rate unknown; requires full $1,500 upfront payment). Captured September 4, 2026.

PlexusDx 6-month commitment: $249/month × 12 = $2,988 over 12 months (our calculation; monthly billing, no upfront payment required).

Difference: AltRx's prepaid promotional tier costs $1,488 less over 12 months, but requires $1,500 upfront and expires September 5, 2026.

The billing-conflict question

AltRx's promotional page states "cancel anytime" in its contract terms (captured September 4, 2026). However, individual reports on Trustpilot and Reddit allege unexpected annual prebilling despite selecting month-to-month plans (captured September 4, 2026). We cannot verify these reports independently, but the conflict is material: if a month-to-month subscriber is billed annually upfront, the effective cash requirement jumps from $89 to $1,068 for semaglutide or $149 to $1,788 for tirzepatide, eliminating the month-to-month flexibility advantage.

PlexusDx does not offer prepaid annual plans and bills month-to-month or at the interval of the selected commitment tier. No billing-conflict reports were captured for PlexusDx as of September 4, 2026.

Practical step: If you select an AltRx month-to-month plan, confirm at checkout whether you will be charged monthly or annually, and review the cancellation policy in writing before submitting payment.

Promotional expiration and rate uncertainty

Every AltRx price in this comparison is labeled promotional and expires September 5, 2026. No standard ongoing rate is documented on AltRx's website as of our September 4, 2026 capture. This creates decision risk: a subscriber who enrolls under the $89 semaglutide promotional rate on September 4 may face a higher undisclosed rate on September 6, and the magnitude of that increase is unknown.

PlexusDx publishes one rate with no promotional cycles. The advertised price is the ongoing price, captured September 4, 2026. This eliminates post-promotion rate shock but costs more upfront during AltRx's promotional window.

What the price difference buys

Both providers include medical oversight, medication, support, and shipping in their advertised rates. Both work with compounding pharmacies to supply non-FDA-approved GLP-1 formulations. The principal service differences are pricing transparency and billing predictability, not clinical scope.

AltRx's promotional pricing model may appeal to cost-focused users willing to accept promotional expiration risk and prepayment requirements. PlexusDx's flat-rate model trades lower advertised prices for rate certainty and simpler billing.

Choose AltRx if…

• You are enrolling before September 5, 2026, and are comfortable with promotional pricing that may change after that date.
• You have the cash flow to prepay 12 months upfront ($900 semaglutide, $1,500 tirzepatide) to access the lowest promotional per-month calculated rate.
• You are willing to confirm billing terms at checkout given individual reports alleging unexpected annual charges on month-to-month plans.
• The lowest possible monthly calculated rate during a promotional window outweighs rate certainty after the promotion expires.

Choose PlexusDx if…

• You want one published rate with no promotional cycles, expiration dates, or post-promotion rate increases.
• You prefer monthly billing over lump-sum prepayment, even at a higher per-month cost.
• You value a provider with no documented billing-conflict reports and transparent cancellation terms.
• You are comparing after September 5, 2026, and AltRx's standard rates (if published) exceed PlexusDx's flat rates.
• You want access to oral semaglutide, oral tirzepatide, or microdose maintenance protocols not offered by AltRx.

Methodology and freshness

AltRx pricing, terms, and promotional expiration date captured September 4, 2026, from altrx.com/glp1/offer-v9-fl and altrx.com homepage. PlexusDx pricing captured September 4, 2026, from plexusdx.com/products/semaglutide-injection and plexusdx.com/products/tirzepatide-injection. Billing-conflict reports captured September 4, 2026, from third-party review platforms (Trustpilot, Reddit). All 12-month cost calculations are our calculations based on the captured monthly or prepaid rates. Prepaid per-month calculated rates (e.g., $75/month for AltRx's $900 12-month semaglutide tier) are our calculations and represent the total cost divided by 12; these figures require full upfront payment and do not imply monthly billing. AltRx's promotional pricing expires September 5, 2026; readers should confirm current rates at altrx.com if viewing this comparison after that date.

Frequently Asked Questions

Does AltRx charge monthly or annually on month-to-month plans?

AltRx's website states "cancel anytime," but individual Trustpilot and Reddit reports allege unexpected annual prebilling despite selecting month-to-month. We recommend confirming the billing interval and total charge at checkout before submitting payment, and reviewing the cancellation policy in writing.

What happens to AltRx pricing after September 5, 2026?

All AltRx pricing captured in this comparison is promotional and expires September 5, 2026. Standard ongoing rates are not documented on AltRx's website as of our September 4, 2026, capture. Confirm current pricing at altrx.com if you are reading this article after the promotional deadline.

Can I switch from semaglutide to tirzepatide mid-treatment?

Switching between GLP-1 medications requires a new provider evaluation and prescription. Neither AltRx nor PlexusDx guarantees automatic switches. A licensed clinician determines whether a medication change is appropriate for an individual patient based on response, tolerability, and clinical goals.

Are compounded semaglutide and tirzepatide interchangeable with Wegovy, Ozempic, and Mounjaro?

No. Compounded medications are not FDA-approved and are not interchangeable with branded drugs. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. Both AltRx and PlexusDx offer compounded formulations; a licensed clinician determines whether a prescription is appropriate for an individual patient.

Does PlexusDx offer prepaid annual plans like AltRx?

No. PlexusDx offers 3-month and 6-month commitment plans with monthly billing (e.g., $149/month semaglutide on a 6-month commitment). These plans do not require upfront payment of the full commitment period. AltRx's prepaid tiers require the full amount upfront (e.g., $900 for 12 months of semaglutide).

Sources

• PlexusDx Semaglutide Injection product page, plexusdx.com/products/semaglutide-injection, accessed September 4, 2026
• PlexusDx Tirzepatide Injection product page, plexusdx.com/products/tirzepatide-injection, accessed September 4, 2026
• AltRx promotional landing page, altrx.com/glp1/offer-v9-fl, accessed September 4, 2026
• AltRx homepage, altrx.com, accessed September 4, 2026
• Third-party review platforms (Trustpilot, Reddit) for billing-conflict reports, accessed September 4, 2026

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. PlexusDx works with licensed 503A compounding pharmacies. A licensed clinician determines whether a prescription is appropriate for an individual patient.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.